CMN Weekly (20 December 2024) - Your Weekly CRISPR...
CMN Weekly
Dec. 20, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Avance Biosciences
Company type: CRO
Main focus: Genomics and molecular biology assays
Company stage: Actively providing services
Diseases: None
Genome-editing tool: N/A
Funding stage: N/A
Location: Houston, Texas, USA
Website: https://www.avancebio.com
Pipeline: N/A
Partners:
Avance Biosciences primarily focuses on providing CGMP- and GLP-compliant genomics and molecular biology services. The company offers sensitive and high-throughput amplicon sequencing to accurately quantify on-target editing efficiency and off-target editing events at predicted loci, including chromosome translocation events. They also offer a range of services related to genotyping, gene expression analysis, and other molecular biology techniques for various applications including CRISPR and CAR-T cells.
